FENC insider transaction filings
FENNEC PHARMACEUTICALS INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-16. Screen FENC transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 21 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 6 filings by 4 insiders — 132,144 shares, $1,506,444 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
- Largest priced transaction: sale of 75,000 shares @ $11.78 ($883,500) by Andrade Robert, filed 2026-08-28.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Andrade Robert — CHIEF FINANCIAL OFFICER | 4 | — | 1 leg · 75,000 sh · $883,500 | 5 |
| Raykov Rosty | 4 | — | 3 legs · 29,599 sh · $316,826 | 5 |
| Brughera Marco Maria — Director | 1 | — | 1 leg · 15,545 sh · $159,958 | 2 |
| Sayad Pierre Sargis — Chief Medical Officer | 3 | — | 1 leg · 12,000 sh · $146,160 | 3 |
| Cioffi Christiana Marie — Chief Strategy Officer | 3 | — | — | 3 |
| Evans Terry L — Chief Commercial Officer | 3 | — | — | 3 |
| Hackman Jeffrey S. — Chief Executive Officer, Director | 3 | — | — | 3 |
Recent Form 4 filings — FENNEC PHARMACEUTICALS INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-16 | 4 | Brughera Marco Maria — Director | Option exercise (M): 15,545 @ $2.11 · Sale (S): 15,545 @ $10.29 · Option exercise (M): 15,545 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Raykov Rosty | Grant/award (A): 2,778 @ $0 · Sale (S): 10,000 @ $12.11 | EDGAR |
| 2026-08-31 | 4 | Cioffi Christiana Marie — Chief Strategy Officer | Grant/award (A): 156 @ $0 | EDGAR |
| 2026-08-31 | 4 | Evans Terry L — Chief Commercial Officer | Grant/award (A): 168 @ $0 | EDGAR |
| 2026-08-31 | 4 | Sayad Pierre Sargis — Chief Medical Officer | Grant/award (A): 168 @ $0 · Sale (S): 12,000 @ $12.18 | EDGAR |
| 2026-08-31 | 4 | Hackman Jeffrey S. — Chief Executive Officer, Director | Grant/award (A): 1,159 @ $0 | EDGAR |
| 2026-08-31 | 4 | Andrade Robert — CHIEF FINANCIAL OFFICER | Grant/award (A): 1,703 @ $0 | EDGAR |
| 2026-08-28 | 4 | Andrade Robert — CHIEF FINANCIAL OFFICER | Sale (S): 75,000 @ $11.78 · Option exercise (M): 21,928 @ $5.10 · Option exercise (M): 21,928 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | Raykov Rosty | Sale (S): 10,000 @ $9.58 | EDGAR |
| 2026-08-03 | 4 | Andrade Robert — CHIEF FINANCIAL OFFICER | Grant/award (A): 1,703 @ $0 | EDGAR |
| 2026-08-03 | 4 | Raykov Rosty | Grant/award (A): 2,778 @ $0 | EDGAR |
| 2026-08-03 | 4 | Hackman Jeffrey S. — Chief Executive Officer, Director | Grant/award (A): 1,159 @ $0 | EDGAR |
| 2026-08-03 | 4 | Cioffi Christiana Marie — Chief Strategy Officer | Grant/award (A): 156 @ $0 | EDGAR |
| 2026-08-03 | 4 | Evans Terry L — Chief Commercial Officer | Grant/award (A): 168 @ $0 | EDGAR |
| 2026-08-03 | 4 | Sayad Pierre Sargis — Chief Medical Officer | Grant/award (A): 168 @ $0 | EDGAR |
| 2026-07-02 | 4 | Raykov Rosty | Grant/award (A): 2,778 @ $0 · Option exercise (M): 15,597 @ $2.45 · Sale (S): 9,599 @ $10.41 · Option exercise (M): 15,597 (derivative) @ $2.45 | EDGAR |
| 2026-07-01 | 4 | Cioffi Christiana Marie — Chief Strategy Officer | Grant/award (A): 156 @ $0 | EDGAR |
| 2026-07-01 | 4 | Sayad Pierre Sargis — Chief Medical Officer | Grant/award (A): 168 @ $0 | EDGAR |
| 2026-07-01 | 4 | Evans Terry L — Chief Commercial Officer | Grant/award (A): 168 @ $0 | EDGAR |
| 2026-07-01 | 4 | Hackman Jeffrey S. — Chief Executive Officer, Director | Grant/award (A): 1,159 @ $0 | EDGAR |
| 2026-07-01 | 4 | Andrade Robert — CHIEF FINANCIAL OFFICER | Grant/award (A): 1,703 @ $0 | EDGAR |
| 2026-06-10 | 4 | Cook Jodi A — Director | Grant/award (A): 20,000 (derivative) @ $8.70 | EDGAR |
| 2026-06-10 | 4 | Islam Khalid — Director | Grant/award (A): 25,000 (derivative) @ $8.70 | EDGAR |
| 2026-06-10 | 4 | Brughera Marco Maria — Director | Grant/award (A): 20,000 (derivative) @ $8.70 | EDGAR |
| 2026-06-10 | 4 | RALLIS CHRIS A — Director | Grant/award (A): 20,000 (derivative) @ $8.70 | EDGAR |
| 2026-06-02 | 4 | Raykov Rosty — Director | Grant/award (A): 2,778 @ $0 · Option exercise (M): 15,597 @ $2.45 · Sale (S): 9,747 @ $9.62 · Option exercise (M): 15,597 (derivative) @ $2.45 | EDGAR |
| 2026-06-01 | 4 | Cioffi Christiana Marie — Chief Strategy Officer | Grant/award (A): 156 @ $0 | EDGAR |
| 2026-06-01 | 4 | Sayad Pierre Sargis — Chief Medical Officer | Grant/award (A): 168 @ $0 | EDGAR |
| 2026-06-01 | 4 | Evans Terry L — Chief Commercial Officer | Grant/award (A): 168 @ $0 | EDGAR |
| 2026-06-01 | 4 | Hackman Jeffrey S. — Chief Executive Officer, Director | Grant/award (A): 1,159 @ $0 | EDGAR |
| 2026-06-01 | 4 | Andrade Robert — CHIEF FINANCIAL OFFICER | Grant/award (A): 1,703 @ $0 | EDGAR |
| 2026-05-12 | 4 | RALLIS CHRIS A — Director | Option exercise (M): 14,344 @ $2.44 · Sale (S): 8,346 @ $7.04 · Option exercise (M): 14,344 (derivative) @ $2.44 | EDGAR |
| 2026-05-01 | 4 | Cioffi Christiana Marie — Chief Strategy Officer | Option exercise (M): 155 @ $0 | EDGAR |
| 2026-05-01 | 4 | Sayad Pierre Sargis — Chief Medical Officer | Option exercise (M): 168 @ $0 | EDGAR |
| 2026-05-01 | 4 | Evans Terry L — Chief Commercial Officer | Option exercise (M): 168 @ $0 | EDGAR |
| 2026-05-01 | 4 | Hackman Jeffrey S. — Chief Executive Officer, Director | Option exercise (M): 1,159 @ $0 | EDGAR |
| 2026-05-01 | 4 | Raykov Rosty — Director | Option exercise (M): 2,778 @ $0 · Option exercise (M): 15,598 @ $2.45 · Sale (S): 10,781 @ $6.47 · Option exercise (M): 15,598 (derivative) @ $2.45 | EDGAR |
| 2026-05-01 | 4 | Andrade Robert — CHIEF FINANCIAL OFFICER | Option exercise (M): 1,703 @ $0 | EDGAR |
| 2026-04-02 | 4 | Cioffi Christiana Marie — Chief Strategy Officer | Option exercise (M): 17,106 @ $0 · Option exercise (M): 158 @ $0 · Option exercise (M): 1,901 @ $0 · Grant/award (A): 120,000 (derivative) @ $5.77 | EDGAR |
| 2026-04-02 | 4 | Sayad Pierre Sargis — Chief Medical Officer | Option exercise (M): 18,456 @ $0 · Option exercise (M): 171 @ $0 · Option exercise (M): 2,052 @ $0 · Grant/award (A): 120,000 (derivative) @ $5.77 | EDGAR |
| 2026-04-02 | 4 | Evans Terry L — Chief Commercial Officer | Option exercise (M): 18,456 @ $0 · Option exercise (M): 171 @ $0 · Option exercise (M): 2,052 @ $0 · Grant/award (A): 120,000 (derivative) @ $5.77 | EDGAR |
| 2026-04-02 | 4 | Hackman Jeffrey S. — Chief Executive Officer, Director | Option exercise (M): 16,695 @ $0 · Option exercise (M): 1,159 @ $0 · Option exercise (M): 13,943 @ $0 · Grant/award (A): 200,000 (derivative) @ $5.77 | EDGAR |
| 2026-04-02 | 4 | Raykov Rosty — Director | Grant/award (A): 5,208 @ $0 · Option exercise (M): 15,598 @ $2.45 · Sale (S): 10,946 @ $6.31 · Option exercise (M): 15,598 (derivative) @ $2.45 | EDGAR |
| 2026-04-02 | 4 | Andrade Robert — CHIEF FINANCIAL OFFICER | Option exercise (M): 14,724 @ $0 · Option exercise (M): 2,213 @ $0 · Option exercise (M): 12,270 @ $0 · Grant/award (A): 120,000 (derivative) @ $5.77 | EDGAR |
| 2026-03-26 | 4 | Cioffi Christiana Marie — Chief Strategy Officer | Option exercise (M): 4,700 @ $4.23 · Option exercise (M): 4,700 (derivative) @ $4.23 | EDGAR |
| 2026-03-26 | 4 | Andrade Robert — CHIEF FINANCIAL OFFICER | Option exercise (M): 13,072 @ $5.10 · Option exercise (M): 13,072 (derivative) @ $5.10 | EDGAR |
| 2026-03-03 | 4 | Raykov Rosty — Director | Option exercise (M): 15,598 @ $2.45 · Sale (S): 10,079 @ $8.36 · Grant/award (A): 5,208 @ $0 · Option exercise (M): 15,598 (derivative) @ $2.45 | EDGAR |
| 2026-03-03 | 4 | Andrade Robert — CHIEF FINANCIAL OFFICER | Grant/award (A): 1,191 @ $0 | EDGAR |
| 2026-02-19 | 4 | Hackman Jeffrey S. — Chief Executive Officer, Director | Option exercise (M): 13,710 @ $0 | EDGAR |
| 2026-02-19 | 4 | Andrade Robert — CHIEF FINANCIAL OFFICER | Option exercise (M): 2,450 @ $4.08 · Option exercise (M): 27,285 @ $0 · Option exercise (M): 2,450 (derivative) @ $4.08 | EDGAR |
Recent 8-K events — FENNEC PHARMACEUTICALS INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-17 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-04-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-24 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-04 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FENC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →